



Published in final edited form as:

*Angew Chem Int Ed Engl.* 2013 April 8; 52(15): 4160–4164. doi:10.1002/anie.201209229.

## Chemically Exfoliated MoS<sub>2</sub> as Near-Infrared Photothermal Agents\*\*

**Stanley S. Chou,**

Department of Materials Science and Engineering, International Institute of Nanotechnology, Northwestern University, Evanston, IL 60208 (USA)

**Dr. Bryan Kaehr,**

Advanced Materials Laboratory Sandia National Laboratories, Albuquerque, NM 87106 (USA)

Department of Chemical and Nuclear Engineering Center for Micro-engineered Materials, University of New Mexico, Albuquerque, NM 87106 (USA)

**Jaemyung Kim,**

Department of Materials Science and Engineering, International Institute of Nanotechnology, Northwestern University, Evanston, IL 60208 (USA)

**Brian M. Foley,**

Department of Materials Science and Engineering, International Institute of Nanotechnology, Northwestern University, Evanston, IL 60208 (USA)

**Dr. Mrinmoy De,**

Department of Materials Science and Engineering, International Institute of Nanotechnology, Northwestern University, Evanston, IL 60208 (USA)

**Prof. Patrick E. Hopkins,**

Department of Mechanical and Aerospace Engineering, University of Virginia, Charlottesville, VA 22904 (USA)

**Prof. Jiaying Huang,**

Department of Materials Science and Engineering, International Institute of Nanotechnology, Northwestern University, Evanston, IL 60208 (USA)

**Prof. C. Jeffrey Brinker, and**

Advanced Materials Laboratory Sandia National Laboratories, Albuquerque, NM 87106 (USA)

---

\*\*B.K. and C.J.B. acknowledge support from the U.S. Department of Energy (DOE), Office of Science, Office of Basic Energy Sciences (BES), Division of Materials Sciences and Engineering. Sandia National Laboratories is a multi-program laboratory managed and operated by Sandia Corporation, a wholly owned subsidiary of Lockheed Martin Corporation, for the U.S. Department of Energy's National Nuclear Security Administration under contract number DE-AC04-94AL85000. S.C. thanks D.H.S. for a fellowship and Dr. Y. Lin for helpful discussions. V.P.D. acknowledges support by the National Cancer Institute Center for Cancer Nanotechnology Excellence (CCNE) initiative at Northwestern University award number U54A119341. J.H. acknowledges support from the National Science Foundation (DMR CAREER grant number 0955612) and the Alfred P. Sloan Research Foundation.

© 2013 Wiley-VCH Verlag GmbH & Co. KGaA, Weinheim

Correspondence to: Stanley S. Chou, s-chou@northwestern.edu; Bryan Kaehr, bjkaehr@sandia.gov.

Supporting information for this article is available on the WWW under <http://dx.doi.org/10.1002/anie.201209229>.

Department of Chemical and Nuclear Engineering Center for Micro-engineered Materials,  
University of New Mexico, Albuquerque, NM 87106 (USA)

**Prof. Vinayak P. Dravid**

Department of Materials Science and Engineering, International Institute of Nanotechnology,  
Northwestern University, Evanston, IL 60208 (USA)

Stanley S. Chou: s-chou@northwestern.edu; Bryan Kaehr: bkaehr@sandia.gov

**Keywords**

dichalcogenides; molybdenum; organic—inorganic hybrid composites; photothermal therapy;  
supramolecular chemistry

The near-infrared (NIR) window refers to a range of wavelengths (700–1300 nm) in which biological tissues are highly transparent.<sup>[1]</sup> Consequently, biological imaging and therapy modalities employ light at these wavelengths for the monitoring<sup>[1]</sup> and triggering<sup>[2]</sup> of biological events in vitro and in vivo. For instance, photothermal ablation takes advantage of NIR absorbing materials for transducing light into heat.<sup>[2]</sup> The resultant thermal energy can be used for a number of applications, such as tissue ablation and drug release. Despite the intense interest in NIR photothermal agents, their development has suffered from considerable challenges. In particular, few nanomaterials display the requisite absorption profiles required for NIR photothermal transduction.

The initial development of NIR photothermal agents largely focused on anisotropic gold particles<sup>[3]</sup> such as nanorods,<sup>[2]</sup> nanocages,<sup>[4]</sup> and nanostars.<sup>[5]</sup> These shapes serve as local plasmon antennas for NIR absorbance, but they are encumbered by complicated syntheses. More importantly, because of the non-equilibrium morphologies, anisotropic gold nanostructures inevitably tend to evolve into spheres upon heating.<sup>[5]</sup>

Consequently, researchers have begun to investigate the NIR photothermal properties of graphene derivatives such as graphene oxide (GO)<sup>[6]</sup> and reduced graphene oxide (rGO).<sup>[7]</sup> The exceptional surface-area-to-mass ratio of these two-dimensional (2D) materials makes them promising photothermal candidates that can be loaded with high cargo concentrations. Previously graphene,<sup>[8]</sup> rGO,<sup>[9]</sup> and MoS<sub>2</sub><sup>[10]</sup> among others<sup>[11]</sup> have been explored for their use as photo-detectors. However, a NIR photocurrent response for mechanically exfoliated MoS<sub>2</sub> phototransistors was negligible.<sup>[10]</sup> Additionally, the efficacy of GO as a NIR photothermal transducer has been debated,<sup>[7a]</sup> prompting investigation of rGO, as a 2D nanomaterial with potentially improved NIR absorbance.<sup>[7a]</sup> Unfortunately, rGO is hydrophobic,<sup>[12]</sup> and thus requires complex surface modifications to be useful in aqueous environments.<sup>[7]</sup>

As an alternative to the aforementioned materials, we report the NIR-photothermal properties of chemically exfoliated MoS<sub>2</sub> (ceMoS<sub>2</sub>). ceMoS<sub>2</sub> is a mixed phase, two-dimensional amphiphile that is easy to synthesize in large batches and is directly dispersible in water.<sup>[13]</sup> Further, the magnitude of its  $\zeta$  potential (−45 mV, comparable to GO)<sup>[14]</sup> provides great colloidal stability in aqueous media. We show that owing to an absorbance

profile reaching into the NIR, ceMoS<sub>2</sub> heats up rapidly upon NIR irradiation. Because of its high surface-area-to-mass ratio, ceMoS<sub>2</sub> also possesses loading capacities on par with GO, the current best-in-class.<sup>[15]</sup> Clearly, ceMoS<sub>2</sub> possesses many desirable traits present in the aforementioned photothermal agents.

To synthesize ceMoS<sub>2</sub>, we use the Morrison method<sup>[13a,c]</sup> which breaks the weak interlayer forces in bulk MoS<sub>2</sub> through ultrasonication and the formation of H<sub>2</sub> gas. Compared to mechanical exfoliation<sup>[16]</sup> or vapor-deposited films on wafer templates,<sup>[17]</sup> the MoS<sub>2</sub> sheets obtained through this method tend to lack the crystallinity required for usage as semiconducting active layers.<sup>[13c,18]</sup> However, this method renders the resulting sheets water dispersible (they are natively hydrophobic), is scalable, and can be readily adapted for other transition metal dichalcogenides.<sup>[13c,19]</sup> A typical synthesis produces approximately 300 mL of MoS<sub>2</sub> at a concentration 300 ppm (see the Experimental Section) and is easily scalable. Physical characterization of the resultant sheets using atomic force microscopy ( $n = 100$ ) revealed mean longest diagonals of 0.80  $\mu\text{m}$  with an average thickness of 1.56 nm ( $n = 40$  sheets), which is consistent with a MoS<sub>2</sub> monolayer<sup>[20]</sup> (Figure 1 and Figure S1 in the Supporting Information).

NIR absorbance by ceMoS<sub>2</sub> was then characterized (Figure 2a). Here, the concentration of ceMoS<sub>2</sub> was determined using induction-coupled plasma mass spectroscopy (ICP-MS), which provides parts-per-billion sensitivity (ppb). This enabled the accurate quantification of the ceMoS<sub>2</sub> mass extinction coefficient ( $\lambda = 800$  nm,  $29.2 \text{ Lg}^{-1} \text{ cm}^{-1}$ ), which represents a  $\approx 7.8$ -fold increase compared to nano-GO ( $3.6 \text{ Lg}^{-1} \text{ cm}^{-1}$ ) and is comparable to nano-rGO ( $24.6 \text{ Lg}^{-1} \text{ cm}^{-1}$ ).<sup>[7a]</sup> It also represents a two times increase over gold nanorods ( $13.9 \text{ Lg}^{-1} \text{ cm}^{-1}$ ).<sup>[7a]</sup>

Next, we investigated photothermal heating of solutions of ceMoS<sub>2</sub>, prepared over a range of concentrations, by irradiation with a continuous wave laser at  $\lambda = 800$  nm ( $0.8 \text{ W cm}^{-2}$ ) and measurement of the solution temperature as a function of time (Figure 2b.). Here, the superior NIR photothermal transduction by ceMoS<sub>2</sub> is demonstrated, as we observed solution temperatures above 40°C, the figure of merit for thermal ablation therapy,<sup>[21]</sup> to be generated with very low concentrations of ceMoS<sub>2</sub> (<38 ppm). This is a marked improvement over GO.<sup>[7a]</sup> Thus, ceMoS<sub>2</sub> combines the NIR heating features of rGO,<sup>[7a]</sup> with the water dispersibility of GO using a simple and readily scalable batch process. Additionally, x-ray photoelectron spectroscopy (XPS) showed no significant oxidation of as prepared and IR-irradiated ceMoS<sub>2</sub> (Figure S2).

To show that ceMoS<sub>2</sub>, in the absence of NIR irradiation, is otherwise biocompatible, we examined its capability to form non-denaturing host-guest interactions with  $\alpha$ -chymotrypsin (ChT), a serine protease. Here, ChT was chosen for its broad bio-sensing applicability and its well documented loading capacity in a wide variety of materials, including gold nanoparticles,<sup>[22]</sup> polymeric micelles,<sup>[23]</sup> dendrimers,<sup>[24]</sup> porphyrins,<sup>[25]</sup> carbon nanotubes,<sup>[26]</sup> and GO.<sup>[14a,15]</sup> As ChT contains a cationic active site that can complex with anionic materials through electrostatic complementation, its loading can be quantified by monitoring enzymatic inhibition by ceMoS<sub>2</sub>. To investigate ChT loading on ceMoS<sub>2</sub>, we incubated a range of concentrations of ceMoS<sub>2</sub> with 16  $\mu\text{M}$  ChT in 96 well plates. After 30

minutes of incubation, *N*-succinyl-L-phenylalanine-*p*-nitroanilide (SPNA), a chromogenic substrate for measuring ChT activity was added to a final concentration of 2 mM. The data were then fitted using nonlinear regression. From the resulting inhibition curve (Figure 3a), it can be seen that 50% of ChT is inhibited by 5 ppm of ceMoS<sub>2</sub>. Full inhibition (> 95%) is attained at 11 ppm. This value is significant, as it demonstrates that ceMoS<sub>2</sub> has a ChT dose-inhibition capacity comparable to GO, which is the current benchmark material (full comparison in the Supporting Information).<sup>[15]</sup>

To show that the host-guest interaction between ChT and ceMoS<sub>2</sub> is reversible, we incubated ChT with 11 ppm of ceMoS<sub>2</sub> (full inhibition concentration) in media of increasing ionic strength to negate electrostatic interactions.<sup>[27]</sup> In one set of experiments, ceMoS<sub>2</sub> was added to ChT in media prespiked with NaCl (pre-incubated). In another set of experiments, NaCl was added after first allowing ceMoS<sub>2</sub> and ChT to form a complex for 30 minutes (post-incubated). In the case of pre-incubation with NaCl, 100% of ChT activity was observed to be recovered at [NaCl] = 750 mM. Comparatively, only 90% of ChT activity was recovered if NaCl was added after ceMoS<sub>2</sub> was allowed to first form a complex with ChT (Figure 3b). Interestingly, the rate of recovery did not change with increased pre-incubation times (24 h, see the Supporting Information). These observations suggest that either some part of ChT is denatured following complexation with ceMoS<sub>2</sub>, or that there may be a two component complexation process where one component acts through non-electrostatic forces.<sup>[15]</sup>

To distinguish between these mechanisms, we investigated the protein structure of ChT after complexation with ceMoS<sub>2</sub> using circular dichroism (CD) and fluorescence spectroscopy. Here, using CD, it can be seen that native ChT structure presents characteristic minima at 232 and 204 nm (Figure 4a and Figure S3).<sup>[15]</sup> Upon denaturation (DChT), the minimum at 232 nm diminishes and the minimum at 204 nm intensifies and shifts toward 198 nm (Figure S3). It can also be seen that ChT, once inhibited by complexation with ceMoS<sub>2</sub>, displays identical CD spectra to free ChT (Figure 4a). In fact, the CD spectra of ChT remained consistent even after 24 h of incubation with ceMoS<sub>2</sub>, thus indicating complexation does not lead to protein denaturation.

The preservation of the ChT structure was also corroborated by fluorescence spectroscopy. Here, as the secondary structure of ChT unravels, its tryptophan (trp) residue becomes increasingly exposed to water. This causes a red-shift in its fluorescence peak, from 334 to 352 nm (Figure S3).<sup>[28]</sup> As this shift was not observed with the inhibited ChT-ceMoS<sub>2</sub>, the fluorescence spectroscopy data corroborates the findings of the CD study (Figure 4b). It is therefore likely that the 90% recovery seen for ceMoS<sub>2</sub>-complexed ChT post-incubated with NaCl is due to a two-component binding process, with the majority due to electrostatic complementarity, and the remaining (non-recovered) binding due to weak intermolecular forces<sup>[15,22]</sup> attributable to the amphiphillic properties of ceMoS<sub>2</sub>.<sup>[13b]</sup>

The combination of biomolecular friendliness, high protein loading, and favorable photothermal characteristics of ceMoS<sub>2</sub> suggests its potential as an effective NIR photothermal agent. To demonstrate this potential, we irradiated aliquots of ChT-complexed ceMoS<sub>2</sub> with NIR light for 15 minutes ( $\lambda = 800$  nm,  $0.8$  W cm<sup>-2</sup>). After treatments,

secondary structures of ChT were examined with CD and fluorescence spectroscopy (Figure 4a,b and Figure S3). Residual activity was monitored by spiking samples with NaCl (750 mM) and reversing the ChT–ceMoS<sub>2</sub> complexation. The activity of ChT after various treatments is shown in Figure 4c.

In these experiments, it can be seen that the ChT–ceMoS<sub>2</sub> complexes irradiated with NIR laser light showed complete denaturation (Figure 4a,b and Figure S3). Further, they show little enzymatic activity (Figure 4c). This demonstrates ceMoS<sub>2</sub> as an effective enzymatic receptor capable of selective destruction of its targets through NIR photothermal transduction.

To demonstrate the photothermal ablation therapy for mammalian cells, we then examined its administration in vitro. Here, we collected Hela cells at a concentration of 10<sup>5</sup> mL<sup>-1</sup>. The solution was then spiked with ceMoS<sub>2</sub> to final concentrations of 20 and 40 ppm. These dosages are roughly an order of magnitude lower than those reported in previous GO studies.<sup>[6b,29]</sup> As with ChT experiments, parallel aliquots were used for controls. All experiments were performed in independent triplicates. After various treatments (irradiated, non-irradiated, with and without ceMoS<sub>2</sub>), cells were washed with phosphate-buffered saline (PBS; three times) and then incubated in a 96 well plate for 24 hrs (10000/well). Cell viabilities were then measured using Celltiter 96 (Promega), a negatively charged, water-soluble MTT agent that does not interfere with cell activity measurements.<sup>[12]</sup>

As shown in Figure 5, cells treated with ceMoS<sub>2</sub> and NIR irradiation ( $\lambda = 800$  nm, 20 minutes) show zero viability at both ceMoS<sub>2</sub> concentrations. This is not surprising as solution temperatures reached 57 and 64°C, respectively, well above thermal ablation thresholds. Optical micrographs of the treated cells confirm the Celltiter results (Figure S4). This presents a stark contrast to cells treated with ceMoS<sub>2</sub> without irradiation. There, cell viabilities of 82 and 81% were observed. It is thus consistent with previous reports showing MoS<sub>2</sub> materials to be relatively non-toxic to cells.<sup>[30]</sup> Cells irradiated with NIR without ceMoS<sub>2</sub> showed a viability of 89%. This observation shows that the photothermal process of ceMoS<sub>2</sub> can be extended for cellular destruction.

As the cellular viability is closely related to the temperature rise induced from the ceMoS<sub>2</sub> photothermal transduction, we examined the physical processes driving the temperature rise in the cellular matrix by measuring the rate of heat transfer from the ceMoS<sub>2</sub> into an aqueous medium with time-domain thermo-transmission (TDTT).<sup>[31]</sup> TDTT has been used previously by several groups to quantify the thermal boundary conductance<sup>[32]</sup> between nanosystems suspended in elastically softer media.<sup>[31, 33]</sup> In short, TDTT uses a brief laser pulse to heat the optically absorbing ceMoS<sub>2</sub> while a time-delayed probe pulse monitors the temperature change of the ceMoS<sub>2</sub>. The thermal decay of the ceMoS<sub>2</sub> over several nanoseconds is related to the heat flow from the ceMoS<sub>2</sub> to the surrounding media, as described in detail elsewhere.<sup>[34, 35]</sup> For our specific TDTT experiments, we measured the thermal decay of 30 ppm of ceMoS<sub>2</sub> suspended in deionized water. We monitored the temperature decay at 800 nm to directly mimic the previously described experiments and find the thermal boundary conductance from the ceMoS<sub>2</sub> to its surrounding to be (77.5±9) MW m<sup>-2</sup> K<sup>-1</sup>. To put this into perspective, this is comparable to the interfacial heat transfer

between two solids<sup>[36]</sup> or between carbon nanotubes and water.<sup>[31, 33b]</sup> This relatively low resistance (high conductance) offers an equivalent resistance of about 10 nm of a typical mammalian cell matrix (assuming a cytoplasmic water content of 70%), indicating the high efficacy of thermal coupling between the ceMoS<sub>2</sub> and the surrounding media. Using this measured value of thermal boundary conductance, from steady-state heat transfer theory<sup>[34, 37]</sup> we calculate a 30 K temperature rise in the intracellular medium for a 30 ppm ceMoS<sub>2</sub> suspensions irradiated at  $\lambda=800$  nm ( $0.8 \text{ W cm}^{-2}$ ).

In summary, we have described the optical and photothermal properties of ceMoS<sub>2</sub> and report its effectiveness as a NIR photothermal agent. ceMoS<sub>2</sub> displays approximately 7.8 times greater absorbance in the NIR relative to GO, with an extinction coefficient at 800 nm of  $29.2 \text{ Lg}^{-1} \text{ cm}^{-1}$ , which is higher than that of gold nanorods ( $13.9 \text{ Lg}^{-1} \text{ cm}^{-1}$ ) and is comparable to rGO ( $24.6 \text{ Lg}^{-1} \text{ cm}^{-1}$ ).<sup>[7a]</sup> Unlike the hydrophobic rGO, however, ceMoS<sub>2</sub> is also directly water dispersible after exfoliation, and easily purified (dialysis under water flow). It also possesses an enhanced biomolecular protein loading capacity comparable to GO, the current best-in-class material.<sup>[15]</sup> These characteristics provide a foundation to explore the use of ceMoS<sub>2</sub> for a wide range of biological applications and beyond (e.g., solar paints and coatings), where broad light absorption into the NIR is desirable.

## Experimental Section

### Synthesis of ceMoS<sub>2</sub>

Procedures were adapted from Joensen et al.<sup>[16]</sup> In a nitrogen environment,  $\approx 350$  mg of MoS<sub>2</sub> powder was immersed in  $\approx 3.5$  mL of *n*-butyllithium (1.6M in hexane) and stirred for 48 h. Mixture was then filtered over Whatman #41 filter and rinsed with 100 mL of hexane. To the semi-dry mixture, 300 mL of H<sub>2</sub>O (18.2 M $\Omega$  cm at 25°C) was added. The mixture was sonicated for 1 h to achieve exfoliation. The MoS<sub>2</sub> nanosheets were then centrifuged and washed with H<sub>2</sub>O five times. It was then collected and dialyzed against H<sub>2</sub>O for 5 days. The concentration was determined by ICP-MS.

Additional experimental details are provided in the Supporting Information.

## Supplementary Material

Refer to Web version on PubMed Central for supplementary material.


## References

1. Jöbsis-vanderVliet FF. *J Biomed Opt.* 1999; 4:392–396. [PubMed: 23014610]
2. Huang X, El-Sayed IH, Qian W, El-Sayed MA. *J Am Chem Soc.* 2006; 128:2115–2120. [PubMed: 16464114]
3. Zhao W, Karp JM. *Nat Mater.* 2009; 8:453–454. [PubMed: 19458645]
4. Skrabalak SE, Chen J, Sun Y, Lu X, Au L, Copley CM, Xia Y. *Acc Chem Res.* 2008; 41:1587–1595. [PubMed: 18570442]
5. Xie J, Lee JY, Wang DIC. *Chem Mater.* 2007; 19:2823–2830.
6. a) Tian B, Wang C, Zhang S, Feng L, Liu Z. *ACS Nano.* 2011; 5:7000–7009. [PubMed: 21815655]  
b) Yang K, Zhang S, Zhang G, Sun X, Lee S-T, Liu Z. *Nano Lett.* 2010; 10:3318–3323. [PubMed: 20684528]


7. a) Robinson JT, Tabakman SM, Liang Y, Wang H, Sanchez Casalongue H, Vinh D, Dai H. *J Am Chem Soc.* 2011; 133:6825–6831. [PubMed: 21476500] b) Yang K, Wan J, Zhang S, Tian B, Zhang Y, Liu Z. *Biomaterials.* 2012; 33:2206–2214. [PubMed: 22169821]
8. Xia F, Mueller T, Lin Y-m, Valdes-Garcia A, Avouris P. *Nat Nanotechnol.* 2009; 4:839–843. [PubMed: 19893532]
9. a) Chang H, Sun Z, Yuan Q, Ding F, Tao X, Yan F, Zheng Z. *Adv Mater.* 2010; 22:4872–4876. [PubMed: 20827686] b) Chitara B, Panchakarla LS, Krupanidhi SB, Rao CNR. *Adv Mater.* 2011; 23:5419–5424. [PubMed: 21786342]
10. Yin Z, Li H, Li H, Jiang L, Shi Y, Sun Y, Lu G, Zhang Q, Chen X, Zhang H. *ACS Nano.* 2012; 6:74–80. [PubMed: 22165908]
11. Rao CNR, Matte HSSR, Subrahmanyam KS. *Acc Chem Res.* 2013; 46:149–159. [PubMed: 22738406]
12. Liao K-H, Lin Y-S, Macosko CW, Haynes CL. *ACS Appl Mater Interfaces.* 2011; 3:2607–2615. [PubMed: 21650218]
13. a) Joensen P, Frindt RF, Morrison SR. *Mater Res Bull.* 1986; 21:457–461. b) Divigalpitiya WMR, Frindt RF, Morrison SR. *Science.* 1989; 246:369–371. [PubMed: 17747918] c) Eda G, Yamaguchi H, Voiry D, Fujita T, Chen M, Chhowalla M. *Nano Lett.* 2011; 11:5111–5116. [PubMed: 22035145]
14. a) Chou SS, De M, Luo J, Rotello VM, Huang J, Dravid VP. *J Am Chem Soc.* 2012; 134:16725–16733. [PubMed: 22962967] b) Luo J, Cote LJ, Tung VC, Tan ATL, Goins PE, Wu J, Huang J. *J Am Chem Soc.* 2010; 132:17667–17669. [PubMed: 21105686]
15. De M, Chou SS, Dravid VP. *J Am Chem Soc.* 2011; 133:17524–17527. [PubMed: 21954932]
16. a) Radisavljevic B, Radenovic A, Brivio J, Giacometti V, Kis A. *Nat Nanotechnol.* 2011; 6:147–150. [PubMed: 21278752] b) Ramakrishna Matte HSS, Gomathi A, Manna AK, Late DJ, Datta R, Pati SK, Rao CNR. *Angew Chem.* 2010; 122:4153–4156. *Angew Chem Int Ed.* 2010; 49:4059–4062.
17. a) Liu K-K, Zhang W, Lee Y-H, Lin Y-C, Chang M-T, Su C-Y, Chang C-S, Li H, Shi Y, Zhang H, Lai C-S, Li L-J. *Nano Lett.* 2012; 12:1538–1544. [PubMed: 22369470] b) Lee Y-H, Zhang X-Q, Zhang W, Chang M-T, Lin C-T, Chang K-D, Yu Y-C, Wang JT-W, Chang C-S, Li L-J, Lin T-W. *Adv Mater.* 2012; 24:2320–2325. [PubMed: 22467187]
18. Joensen P, Crozier ED, Alberding N, Frindt RF. *J Phys C.* 1987; 20:4043.
19. Zeng Z, Yin Z, Huang X, Li H, He Q, Lu G, Boey F, Zhang H. *Angew Chem.* 2011; 123:11289–11293. *Angew Chem Int Ed.* 2011; 50:11093–11097.
20. Late DJ, Liu B, Matte HSSR, Rao CNR, Dravid VP. *Adv Funct Mater.* 2012; 22:1894–1905.
21. a) Huang H-C, Rege K, Heys JJ. *ACS Nano.* 2010; 4:2892–2900. [PubMed: 20387828] b) Huang X, Jain PK, El-Sayed IH, El-Sayed MA. *Photochem Photobiol.* 2006; 82:412–417. [PubMed: 16613493] c) Overgaard J. *Int J Radiat Oncol Biol Phys.* 1989; 16:535–549. [PubMed: 2646256]
22. Fischer NO, McIntosh CM, Simard JM, Rotello VM. *Proc Natl Acad Sci USA.* 2002; 99:5018–5023. [PubMed: 11929986]
23. Sandanaraj BS, Vutukuri DR, Simard JM, Klaikherd A, Hong R, Rotello VM, Thayumanavan S. *J Am Chem Soc.* 2005; 127:10693–10698. [PubMed: 16045357]
24. Chiba F, Hu T-C, Twyman LJ, Wagstaff M. *Chem Commun.* 2008:4351–4353.
25. Kano K, Ishida Y. *Chem Asian J.* 2008; 3:678–686. [PubMed: 18311746]
26. Zhang B, Xing Y, Li Z, Zhou H, Mu Q, Yan B. *Nano Lett.* 2009; 9:2280–2284. [PubMed: 19408924]
27. Verma A, Simard JM, Rotello VM. *Langmuir.* 2004; 20:4178–4181. [PubMed: 15969414]
28. a) Ladokhin, AS. *Encyclopedia of Analytical Chemistry.* Wiley; Hoboken: 2006. b) Fischer NO, Verma A, Goodman CM, Simard JM, Rotello VM. *J Am Chem Soc.* 2003; 125:13387–13391. [PubMed: 14583034]
29. Note: Value calculated from reference [7b] using the reported dose (20 mg kg<sup>-1</sup>) by assuming a typical mouse weight of 250 g and a blood volume of 1.5 mL.
30. Wu H, Yang R, Song B, Han Q, Li J, Zhang Y, Fang Y, Tenne R, Wang C. *ACS Nano.* 2011; 5:1276–1281. [PubMed: 21230008]

31. Huxtable ST, Cahill DG, Shenogin S, Xue L, Ozisik R, Barone P, Usrey M, Strano MS, Siddons G, Shim M, Keblinski P. *Nat Mater.* 2003; 2:731–734. [PubMed: 14556001]
32. Swartz ET, Pohl RO. *Rev Mod Phys.* 1989; 61:605–668.
33. a) Huxtable ST, Cahill DG, Shenogin S, Keblinski P. *Chem Phys Lett.* 2005; 407:129–134. b) Kang SD, Lim SC, Lee E-S, Cho YW, Kim Y-H, Lyeo H-K, Lee YH. *ACS Nano.* 2012; 6:3853–3860. [PubMed: 22468828]
34. Cahill DG. *Rev Sci Instrum.* 2004; 75:5119–5122.
35. a) Hopkins PE, Serrano JR, Phinney LM, Kearney SP, Grasser TW, Harris CT. *J Heat Transfer.* 2010; 132:081302. b) Schmidt AJ, Chen X, Chen G. *Rev Sci Instrum.* 2008; 79:114902. [PubMed: 19045906]
36. Pop E. *Nano Res.* 2010; 3:147–169.
37. Oh D-W, Ko C, Ramanathan S, Cahill DG. *Appl Phys Lett.* 2010; 96:151906.






**Figure 1.** Atomic force microscopy (AFM) micrograph of  $\text{ceMoS}_2$  sheets. The insets show diameter and thickness profiles.




**Figure 2.**

a) Absorbance profile of  $\text{ceMoS}_2$ . The top curve is 5 ppm. Each subsequent curve is 0.5 times diluted. The inset is the Beer's law plot at 800 nm (O.D. = optical density). b) Photothermal heating curves of  $\text{ceMoS}_2$  across a range of concentrations.




**Figure 3.** a) Inhibition of ChT using increasing doses of  $\text{ceMoS}_2$ . b) Activity of ChT- $\text{ceMoS}_2$  pre-incubated and post-incubated with increasing concentrations of NaCl.



**Figure 4.**

a) Normalized CD and b) fluorescent spectra of select ChT samples after various treatments. A full set of samples is available in the Supporting Information (Norm. = normalized intensity). c) Normalized activity assay of ceMoS<sub>2</sub>-ChT or decoupled ChT in 750 mM NaCl after various treatments.



**Figure 5.**  
Hela cell viabilities after various treatments.